C ardiovascular disease (CVD) is a group of disorders affecting the heart and blood vessels including coronary heart disease, stroke, hypertension, and peripheral arterial disease. CVD is caused by interactions of genetic, environmental, and lifestyle factors. 1 During the past half century, prevention and treatment efforts have focused on modifiable CVD risk factors such as elevated blood cholesterol level, hypertension, type 2 diabetes mellitus, and tobacco use. Although these targeted efforts have contributed to steady declines in CVD mortality over this time period, CVD remains the leading cause of death across the globe. 2
is the SH2B3 gene region on chromosome 12, which harbors variants that are associated with myocardial infarction 4 and blood pressure 5 and also with rheumatoid arthritis 6 and type 1 diabetes mellitus. 7 Several common genetic variants associated with coronary artery disease (CAD) or myocardial infarction in GWAS also reveal associations with CVD risk factors and other complex traits, 8 suggesting that these common genetic variants have multiple molecular functions or that they have a single molecular function with multiple downstream consequences. Although pleiotropic effects have been widely observed, their presence in relation to CVD and their downstream effects have not been evaluated systematically.
Despite the identification of thousands of common SNPs that are associated with an increased propensity toward CVD, the variants identified thus far explain only a small fraction of the overall genetic contribution to disease risk. 9 It is likely that disease-promoting SNPs act by affecting the amino acid sequences of the corresponding coded proteins (ie, nonsynonymous SNPs) or by altering mRNA expression levels (ie, expression quantitative trait loci [eQTLs]). 10 A growing number of eQTLs have been found to be associated with human diseases. 11 For example, multiple SNPs that were associated with blood lipid levels in GWAS were also found to be eQTLs for nearby genes (eg, in SORT1, PPP1R3B, and TTC39B), 12 suggesting that eQTLs play an important functional role.
We hypothesized that genetic variants influence CVD phenotypes by altering expression of genes and that systematic analysis of multiple traits might reveal high-order interactions of CVD and its risk factors. 13, 14 To that end, we built a CVD network using SNP-CVD phenotype associations and dissected the relationships between genetic variants, gene expression, and CVD phenotypes. By integrating these 3 layers of information from >5000 Framingham Heart Study (FHS) participants with deep phenotyping for CVD and extensive genotyping and gene expression profiling, we were able to study the role of genetic variation in relation to gene expression and to integrate this information across multiple complex CVD phenotypes. Our results revealed a dense network in which genetic variation was linked to gene expression and CVD phenotypes. We identified several modules that support the existence of pathways affected by genetic variants. We highlighted examples in which genetic variants may play a causal role in CVD and hypothesized that they affect CVD phenotypes by regulating (cis and trans) gene expression. Identifying these genetic variants that mediate gene expression may aid in understanding biological mechanisms underlying CVD and in targeting therapies for its treatment and prevention.
Methods

Study Sample
Beginning in 1948, the FHS recruited participants from Framingham, MA, to undergo biennial examinations to investigate CVD and its risk factors. 15 In 1971 and 2002, offspring (and their spouses) and adult grandchildren of the original cohort participants were recruited into the second-and third-generation cohorts, respectively. Collection of blood samples and RNA preparation were described previously. 16 A total of 5257 participants from the offspring cohort (at examination 8) and third-generation cohort (at examination 2) who had both genomewide genotyping (institutional review board approval No. H-26671) and gene expression profiling (institutional review board approval No. H-27984) were included in this study ( Figure 1 ).
Trait-Associated SNP
A total of 1512 SNPs associated in GWAS with 21 cardiovascular traits (Table 1) with the use of data from the database of Genotypes and Phenotypes (dbGaP) 17 and the National Human Genome Research Institute GWAS catalog 3 (at P≤5×10 −8 , downloaded in January 2014) were curated and matched with Framingham Affymetrix 550K array genotype data. 18 The dbGaP resource lists results of GWAS whether published or not. The National Human Genome Research Institute GWAS catalog lists only published GWAS studies. Genotyping and quality control methods in the FHS have been described previously. 18 Briefly, SNPs were inputted to Minimac, 19 an implementation of genotype imputation software. SNP imputation combined genotype data with the HapMap CEU samples and then inferred genotypes probabilistically on the basis of shared haplotype stretches between study samples and HapMap release 22 build 36. Imputation results were summarized as an "allele dosage," defined as the expected number of copies of the minor allele at that SNP (a fractional value between 0 Figure 1. Flowchart of integromic analysis. A total of 1512 single nucleotide polymorphisms (SNPs) associated with 21 cardiovascular disease (CVD) traits (at P≤5×10 −8 ) were derived from database of Genotypes and Phenotypes and the National Human Genome Research Institute genome-wide association studies (GWAS) catalog. We built a CVD phenotype network by connecting 2 traits if they share the same GWAS SNP. Whole blood samples were collected from 5257 FHS participants. Genome-wide genotyping and mRNA expression levels were assayed. We correlated 1077 SNPs (after genotyping quality control of 1512 SNPs) with 17873 gene expression values to assess expression quantitative trait loci (eQTLs). We replicated these eQTLs in 2 large databases. We then built an eQTL network by connecting eQTLs to their associated genes and traits. We identified modules associated with different CVD traits within the network. Finally, we conducted mediation analyses to test whether the genetic effect appears to influence the CVD phenotype through effects of the eQTL (ie, GWAS SNP) on gene expression. BMI indicates body mass index; FHS, Framingham Heart Study; HDL-C, highdensity lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol.
Gene Expression
Whole blood was collected in PAXgene tubes (PreAnalytiX, Hombrechtikon, Switzerland) and frozen at −80°C. RNA was extracted from whole blood with the use of the RNA System Kit (Qiagen, Venlo, Netherlands), and mRNA expression profiling was assessed with the use of the Affymetrix Human Exon 1.0 ST GeneChip platform (Affymetrix Inc, Santa Clara, CA), which contains >5.5 million probes targeting the expression of 17 873 genes. The Robust Multi-Array Average package 20 was used to normalize the gene expression values and remove any technical or spurious background variation. Linear regression models were used to adjust for technical covariates (batch, first principal component, and residual of all probeset mean values).
Statistical Analysis
eQTL analysis was conducted with the use of the pedigreemm 21 package in R with gene expression as the dependent variable and genotype, sex, and age as independent variables. Technical covariates and imputed whole blood cell counts (or proportions) were adjusted for with the use of a linear mixed effects model. Familial relatedness was modeled as a random effect. The cis effect for a given expression trait was defined by testing all SNPs located within 1 Mb upstream or downstream of the transcription start site of a gene (cis-eQTL). SNPs that were mapped to different chromosomes from their associated gene transcripts were defined as trans-eQTLs. The false discovery rate 22 was applied to account for multiple testing. SNPs at false discovery rate <0.05 were selected as significant eQTLs. For trans-eQTLs that were also cis-eQTLs, we examined whether the genes regulated in cis play a role in the regulation of the trans genes by conditioning on expression of the cis gene in the linear regression model. Mediation analysis was conducted with the use of the mediation package 23 in R with SNP as the "exposure," gene expression as the "mediator," and phenotype as the "outcome." A 100% proportion of mediation effect indicates that the entire association between a SNP and a phenotype (direct effect) is explained by changes in gene expression. The significant mediation effects were selected at a permutation P<0.0005 (based on 10 000 permutations).
Annotation and Enrichment Analysis of eQTLs With Encyclopedia of DNA Elements Data
The Encyclopedia of DNA Elements (ENCODE) 24 cataloged many regulatory elements including DNase I hypersensitive regions profiled in 82 cell lines, 149 transcription factor (TF) binding regions profiled in different cell lines resulting in a total of 406 different cell line-TF pairs, and 162 histone modification-cell line pairs (ENCODE January 21, 2011 freeze). We used GLANET (publication in preparation, software available at https://github.com/burcakotlu/GLANET and documentation at https://glanet.readthedocs.org/en/latest/) to annotate our list of eQTLs by overlapping them with the ENCODE peak lists. We then evaluated the significance of the overlap using GLANET's resampling-based enrichment analysis. Specifically, we sampled multiple (n=100 000) random SNP sets matching in size and numbers per chromosome to the original eQTL SNP set and computed the size of the overlap for each random set. To account for systematic biases, our random sampling scheme took into account the "mappability" and guanine-cytosine content of the SNPs and matched the random SNP sets to the actual SNP set in terms of mappability and guanine-cytosine content. The collection of overlap statistics across multiple random samplings was then used to estimate an empirical null distribution for the overlap statistic. The resulting P values were adjusted for multiple testing using both the Benjamini Hochberg 22 and Bonferroni correction methods. We used the FIMO tool from the MEME suite 25 to assess whether the eQTLs disrupted the binding sites of the TFs that they were bound by in the ENCODE data.
In Silico Validation of eQTLs
Whole blood eQTLs were downloaded from the Blood eQTL Browser. 11 This resource contains the results of an eQTL metaanalysis from 5311 peripheral blood samples from 7 studies. To explore tissue-specific effects, we also collected and analyzed results from 53 eQTL population data sets ( Table I in the online-only Data Supplement). These 53 data sets represent analyses from 24 published manuscripts and 13 unpublished data sets reflecting >27 cell and tissue types. 26 Cis-and trans-eQTLs from the present study were cross-referenced with significant eQTLs reported in the aforementioned data sets directly by matching SNP identifiers.
Network Construction and Modules Identification
On the basis of the SNP-trait relationships, we constructed a CVD network. In the network, each node corresponds to a CVD trait, and 2 traits were connected to each other if they shared at least 1 SNP in GWAS. The width of each edge was weighted by the proportion of shared SNPs between traits. To explore relations between CVD traits and other complex traits (GWAS SNP P<5×10 −8 ), we expanded the connections if SNPs associated with CVD traits were also found to be associated with other diseases in GWAS. Networks were visualized with the use of Cytoscape software. 27 On the basis of SNP-gene expression associations, we constructed an eQTL network. The TFit (iterated Transfer-Fusion) algorithm with default parameters in the Clust&see 28 plugin of Cytoscape was used to search for modules within this network. The TFit algorithm 29 is based on modularity optimization, which uses a vertex transfer procedure at every level. Level 1 is the entire network; each node is assigned to its best adjacent cluster, as long as modularity increases. Then classic transfers were performed, and vertices belonging to the same cluster were merged.
Results
Genetic Variation Network for Complex CVD Traits
We restricted our analysis to 1512 significant GWAS SNPs associated (at P≤5×10 −8 ) with 21 CVD traits listed in Table 1 . Fifteen of the 21 CVD traits shared at least 1 SNP with another trait ( Figure 2 and Table II in the online-only Data Supplement). Among the CVD traits, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, body mass index, type 2 diabetes mellitus, and blood pressure served as "hub" phenotypes that connected multiple CVD traits, mirroring epidemiological observations about the clustering of metabolic risk factors. 30 We found that C-reactive protein and LDL-C had a strong genetic connection via 6 shared SNPs (rs1260326 of GCKR, rs1800961 of HNF4A, rs2075650 of TOMM40, rs2650000 of RPL12P33-NCRNA00262, rs4420638 of APOC1, and rs9987289 of PPP1R3B-TNKS). CAD and LDL-C had a strong genetic connection through 5 shared SNPs (rs11206510 of BSND-PCSK9, rs599839 of PSRC1, rs12740374 and rs646776 of CELSR2, and rs964184 of ZNF259). We also identified some hub SNPs; for example, rs964184, an intronic variant in ZNF259, was associated in GWAS with HDL-C, 31 LDL-C, 12 triglycerides, 12 and CAD. 4 rs1260326 (GCKR) was associated in GWAS with triglycerides, 12 total cholesterol, 12 and C-reactive protein 32 ; rs13107325 (SLC39A8) was associated in GWAS with blood pressure, 5 body mass index, 33 and HDL-C. 12 We further considered SNPs in linkage disequilibrium with an index SNP. Two traits were connected if they shared the same GWAS SNP or proxy SNPs that are in high linkage disequilibrium (r 2 >0.8) with the index SNP. When modified through the inclusion of proxy SNPs, the CVD phenotype network encompassed 19 of the 21 CVD traits ( Figure  I Expanding the connections across all 409 complex traits containing genome-wide significant SNPs within dbGaP and the National Human Genome Research Institute GWAS catalog, we found that CVD-associated SNPs from GWAS were strongly linked with many other complex traits ( Figure II in the onlineonly Data Supplement). These associations include HDL-C and LDL-C with alcohol consumption, Alzheimer disease ( Figure III in the online-only Data Supplement) and blood pressure with CD40 ligand, and resistin with vitamin K levels ( Table III in the online-only Data Supplement). Using this approach, we found that the phenotype network linked by common SNPs may reveal unexpected genetic connections with numerous non-CVD traits.
Regulation of the Genetic Variation Network
At a minor allele frequency >0.01 and imputation r 2 >0.3, 1077 genome-wide significant (P<5×10 −8 ) SNPs from GWAS were available for analysis. At false discovery rate <0.05, we identified 370 cis-eQTLs (associated with expression of 400 genes at P<10 −4 ) and 44 trans-eQTLs (associated with expression of 76 genes at P<10 −6 ; Table IV in the online-only Data Supplement). For 696 SNPs (65%) not associated with expression traits, we further tested the association between their perfect proxy SNPs (linkage disequilibrium r 2 =1 in SNAP) 34 and gene expression levels. Using proxy SNPs, we identified an additional 54 cis-eQTLs for 6 CVD trait-associated SNPs ( Table V in the online-only Data Supplement).
To assess whether the eQTLs significantly overlap with regulatory regions, we performed annotation and enrichment analysis with the DNase, histone modification, and TF peaks from the ENCODE project (see Methods for details). We first annotated each eQTL by intersecting the SNP locus with ENCODE peaks and then evaluated the significance of overlap with (Table VI in the online-only Data Supplement) . Thirty of our eQTLs are located within 10 kb upstream of the transcription start site of the expressed gene associated with the corresponding SNP (Table VI in the online-only Data Supplement). Our annotation analysis indicated that all of these promoter eQTLs are within 1 or more histone modification region, and 10 of them overlap with a TF peak. Notably, rs7528684, which is a cis-eQTL associated with expression of FCRL3, resides 2 kb upstream of the transcription start site of FCRL3 and is bound by Nfkb in the Gm12891 cell line. Our sequence analysis revealed that this SNP is an eQTL that might be regulating expression of FCRL3 by increasing binding affinity of the Nfkb binding site (Figure 3 ).
By connecting eQTLs and their associated genes, we built a SNP-gene association network ( Figure IV in the online-only Data Supplement). Using the TFit algorithm, 28 we identified 13 modules containing >10 nodes (Table VII in the onlineonly Data Supplement) . These modules may reveal genetic pathways affecting CVD phenotypes. For example, SNPs associated with type 1 diabetes mellitus displayed cis associations with genes in 6p21 and trans associations with ROR1 and CTLA4 ( Figure 4A ). Using gene set enrichment analysis, we found that these genes were significantly enriched for the KEGG type 1 diabetes mellitus pathway (P<10 −6 ). Of note, GWAS and gene expression studies have identified association between CTLA4 (DNA and mRNA level) and type 1 diabetes mellitus. 35 In another module, rs964184 in ZNF259, which was associated in GWAS with HDL-C, LDL-C, triglycerides, 12, 31 and CAD, 4 was found to have cis associations with PCSK7, SIDT2, TAGLN, and BUD13 and trans associations with TMEM165, YPEL5, PPM1B, and OBFC2A ( Figure 4B ). Three linked SNPs in FADS1 (rs174546, rs174547, and rs174548; pairwise R 2 =0.80-0.97) were associated in GWAS with multiple lipids traits 36 ; we found that these SNPs have cis associations with C11orf10, FADS1, FADS2, and FEN1 and trans associations with LDLR and SREBF2 ( Figure 4C ). Using gene set enrichment analysis, we found that genes in these 2 modules are significantly enriched for lipid metabolic processes (P<10 −6 ). rs1994016, rs3825807, and rs4380028 (pairwise r 2 =0.52-0.87) in ADAMTS7 were associated in GWAS with CAD, 4 whereas rs1051730 and rs2036527 (pairwise r 2 =0.90) in CHRNA3 were associated in GWAS with smoking. 37, 38 We discovered that these SNPs all displayed cis association with 3 genes (PSMA4, CHRNA5, CTSH). Variants in PSMA4 and CHRNA5 were found to be associated with chronic obstructive pulmonary disease and lung function. 39 The CHRNA5 variants were also found to be associated with nicotine and alcohol dependence. 40 Expression levels of PSMA4 and CTSH were found to regulate immune function in type 1 diabetes mellitus. 41 Therefore, the clustering of these 3 genes with multiple disease-associated SNPs may explain in part the concurrence of CAD and chronic obstructive pulmonary disease and the strong association between smoking, CAD, and diabetes mellitus ( Figure 4D ).
Reproducibility of eQTLs
To validate the eQTLs detected above, we first queried the Blood eQTL Browser 11 meta-analysis of eQTL associations in nontransformed peripheral blood samples from 5311 individuals. A total of 240 cis-eQTLs and 25 trans-eQTLs from our data set were also detected as eQTLs in the Blood eQTL Browser database. Among them, 165 cis-eQTLs (69%) and 25 trans-eQTLs (100%) were associated with expression of the same genes and showed the same directions of association as our eQTL findings. In addition, we found 7 cis-eQTLs from our results that were perfect proxies (r 2 =1) of eQTLs in the Blood eQTL Browser ( Table VIII in the online-only Data Supplement). Because eQTLs are highly tissue specific, 42 we further queried our multitissue eQTL databases, which integrated 53 data sets from multiple tissues (see Methods for details). One hundred sixty-one cis-eQTLs from our data also were detected as eQTLs in this database (no trans-eQTLs were found). Among them, 116 cis-eQTLs (72%) were associated with the same genes across eQTL databases ( Table IX in the online-only Data Supplement). rs17030613 in CAPZA1, associated with blood pressure in GWAS, 43 was associated with the expression of ST7L in our data and in 2 other tissues (brain and CD4 + lymph). Lower ST7L transcript levels were found to be associated with lower blood pressure in East Asian populations. 43 In the FHS samples, we found that ST7L transcript levels were associated with diastolic blood pressure (P=0.023). rs1412444 in LIPA, associated with CAD in GWAS, 44 was associated with expression of LIPA in our data and in 2 other tissues (blood and liver). rs2531995 in ADCY9 was associated with obesity in GWAS 45 and with expression of ADCY9 in our data and in 4 other tissues (brain, blood, liver, and omentum).
SNP Effects on Gene Expression May Mediate Phenotype Variation
To test whether expression levels of genes regulated by eQTLs might explain the observed associations between eQTLs and phenotypes, we tested the association between expression of eQTL genes and 7 metabolic CVD phenotypes (body mass index, LDL-C, HDL-C, triglycerides [log-transformed], fasting blood glucose, and systolic and diastolic blood pressure; Table 2 ) in 5257 FHS participants. We found several examples in which the expression level of the eQTL-associated gene was significantly associated with the same trait that was associated in GWAS with the index SNP (hypergeometric test P<0.001; Table 3 ). For 7 continuous CVD phenotypes that were available for analysis in the FHS, the eQTLs explained 0.5% to 5% of interindividual phenotype variation; in contrast, expression levels of the eQTL genes explained 4% to 13% of interindividual phenotype variation (Table 3 ). These results are consistent with the hypothesis that genetic variation affects phenotypes via effects on gene expression (see Figure 5 for an example).
To test whether the association of a SNP with a phenotype was potentially mediated via its effect on gene expression, we conducted mediation analysis to identify the proportion of the association between a SNP and its corresponding phenotype that was attributable to SNP-related changes in gene expression and subsequent differences in phenotype levels. At P<0.0005 for average causal mediation effects, we identified several potential mediation effects for HDL-C, LDL-C, and triglycerides (Table 4 ; no significant results were obtained for body mass index, fasting blood glucose, or blood pressure). For example, rs174546, rs174547, and rs174548 (intronic to FADS1) were found to be associated in GWAS with multiple metabolic traits (HDL-C, triglycerides, and phospholipids). 31 For these SNPs, we found that 46% of their genetic effect on HDL-C, 59% of their genetic effect on LDL-C, and 47% of their genetic effect on triglycerides were mediated through FADS1 expression (Table 4 ). In addition, as shown in Figure 4C , these 3 SNPs have trans associations with LDLR and SREBF2, which also demonstrate strong mediation effects on HDL-C, LDL-C, and triglycerides: LDLR (19% mediation for HDL-C, 29% mediation for LDL-C, and 15% mediation for triglycerides) and SREBF2 (19% mediation for HDL-C, 28% mediation for triglycerides). rs964184 was reported to Values are mean (SD) unless indicated otherwise. HDL indicates high-density lipoprotein.
*Hypertension: systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or currently taking medication to treat elevated blood pressure. Diabetes mellitus: participants with fasting blood glucose ≥126 mg/ dL or currently taking medication to treat an elevated blood glucose level. February 10, 2015 be associated in GWAS with LDL-C, HDL-C, and CAD. 4, 12 Mediation analyses revealed that a substantial proportion of its genetic effect on lipids is mediated through its trans association with expression of PPM1B (4% mediation of HDL-C and triglycerides) and YPEL5 (7% mediation of HDL-C and 6% mediation of triglycerides). Because the expression levels of all of these genes were associated with HDL-C, LDL-C, or triglyceride levels, the module they constitute may represent an important target for lipid treatment.
Metabolite SNPs and CVD Traits
Metabolomic findings can be used to unravel novel biochemical mechanisms involved in a variety of disease processes, including atherogenesis. To identify genetic and biochemical underpinnings of our CVD network and pathways, we incorporated 170 genome-wide significant SNPs from 2 recently published metabolomic GWAS. 36, 46 We found 13 SNPs that were shared between metabolites and the 21 CVD phenotypes in our network. As shown in Figure 6 , several metabolites are associated with the 21 CVD traits in our network by virtue of shared GWAS SNPs. This was especially notable for lipid traits. For 13 SNPs that were shared between metabolites and the CVD traits in our network ( Figure 6 ), 6 of them were also associated with expression levels of genes (Table 5) , including rs174548 (FADS1), which was associated in GWAS with arachidonic acid (C20:4), a product regulated by FADS1, and with its substrate, dihomolinolenate. These eQTLs belong to 3 eQTL subnetworks ( Figure 4A through 4C ), suggesting genetic regulation of intermediate metabolites or the lipid end-products in our pathways. When we further included perfect proxy SNPs (r 2 =1) for the index GWAS SNPs associated with metabolites and CVD traits, we identified 8 eQTLs for 3 metabolite SNPs (Table X in the online-only Data Supplement) that were associated with additional CVD traits, including variants in ABO associated with venous thrombosis, CAD, and LDL-C.
Discussion
CVD is the consequence of the intricate interplay between multiple genetic variants, clinical risk factors, and environmental factors. Our phenotype network, composed of pleiotropic SNPs, provided evidence of the shared genetic underpinnings of CVD and its risk factors. Our eQTL network, which integrated SNPs, gene expression, and phenotype, identified several pathways affected by genetic variants associated with CVD and its major risk factors.
With the use of GWAS results alone, it is not possible to identify the causal variant, the causal gene, or the mechanism by which a SNP or nearby gene affects the phenotype. By integrating multidimensional data (ie, GWAS SNPs and gene expression analyses), we provide evidence that GWAS loci have strong associations (cis or trans) with expression levels of genes. 47 We replicated our eQTL results in 2 large databases. The relatively low replication of some eQTLs from our data set in other databases may be attributable to the different genotyping and gene expression platforms (the Blood eQTL Browser used iIllumina arrays for SNPs and gene expression, whereas we used an Affymetrix array) or from the fact that our data set arose from a larger single cohort with uniform data collection techniques, whereas the Blood eQTL Browser relied on metaanalysis of many separate data collection efforts. On the other hand, for the eQTLs identified both in our data and in other databases, we found a high concordance of SNP-gene associations, further indicating that these eQTLs are replicable. Many of the genes associated with CVD SNPs were previously reported to be associated with CVD or its risk factors, including FADS1, HMGCR, LPL, LDLR, and SREBF2. Moreover, we found a large number of eQTL-associated genes whose expression levels were also associated with a variety of CVD phenotypes, suggesting the existence of 3-way relationships between genetic variants, gene expression, and phenotypes ( Figure 5) .
The underlying mechanism of downstream effects of disease-associated SNPs (trans-eQTL) has not yet been fully characterized. It has been suggested that expressed cis-eQTL genes can act as master trans regulators. 48 Among 31 eQTLs with both cis and trans associations, we found that only SNPs in the FADS1 region (rs174546, rs174547, and rs174548) lost significance for association with LDLR and SREBF2 after conditioning on expression of the corresponding cis genes (for expression of FADS1 and FADS2, see Table XI in the onlineonly Data Supplement). Both the cis and trans associations were replicated in the Blood eQTL Browser, suggesting that the trans effects on LDLR and SREBF2 were mediated by FADS1 and FADS2 expression. Moreover, both the SNPs in GWAS and gene expression in our samples were associated with multiple lipids traits (HDL-C, LDL-C, and triglycerides), providing evidence of trans effects and implicating this cistrans eQTL module ( Figure 4C ) in the link between FADS gene variation and CVD risk.
Common variants from GWAS explained only a small fraction of interindividual trait variance, yet they may provide important biological or therapeutic insights. For example, common variants in the introns of HMGCR and NPC1L1 confer small effects on plasma LDL-C (3 and 2 mg/dL, respectively), but they have dramatic effects on LDL-C when targeted by statins or ezetimibe, respectively. 12 Using mediation testing, we found that the genetic effects of variants (rs12916, rs3846663, and rs12654264; pairwise R 2 =0.94-1.0) in HMGCR on LDL-C may be mediated through HMGCR expression (P=0.034, P=0.036, and P=0.044, respectively). This analysis also revealed several known as well as potentially novel therapeutic targets. For example, we found that the expression of PCSK7 was not only cis associated with rs964184, a pleiotropic SNP in ZNF259 that is associated in GWAS with HDL-C, LDL-C, triglycerides, and CVD risk, 4, 12 but PCSK7 expression also was associated with LDL-C and triglyceride levels in FHS participants. Thus, part of the genetic effect of rs964184 on LDL-C (8%) and triglycerides (5%) was mediated through expression of PCSK7, providing orthogonal support for this gene as a potential therapeutic target. Of note, a rare coding variant in PCSK7 was recently found to be associated with HDL-C by analysis of exonic variants in individuals of African ancestry. 49 Expression of another gene, FDFT1, revealed cis associations with SNPs associated in GWAS with HDL-C, LDL-C, triglycerides, and coronary disease ( Figure 4E ; light red represents long-range cis associations). The expression of FDFT1 was significantly associated with HDL-C and triglyceride levels (P=1.5×10 −10 and 1.5×10 −7 , respectively) in FHS participants. Moreover, the mediation test for FDFT1 was significant (P<0.001 for average causal mediation effects) on HDL-C. A recent study found that expression of FDFT1 was significantly higher in atherosclerosis-resistant Japanese quail than in atherosclerosis-susceptible strains, 50 suggesting that FDFT1 may represent another potential therapeutic target for the treatment of lipids and atherosclerotic CVD. There are several limitations to this study. First, from this observational study, we can only infer the mediation effects of genetic variants. Causal relationships may be validated through randomized experiments or biological validation studies. Second, our gene expression data were derived from whole blood; some eQTLs may be highly tissue dependent. Therefore, the CVD modules and mediation effects may not be reflective of other tissues. Third, because each SNP only contributes a small effect on phenotypic variation, the combination of SNPs and their interactions may reveal a more complete picture of disease mechanisms.
In summary, integrating published GWAS with genetic variants, gene expression, and phenotype data from >5000 FHS participants allowed us to decipher the genetic architecture that underlies CVD and its risk factors at the population level. The integration of 3 levels of data not only afforded plausible functional explanations for disease but also revealed promising therapeutic targets.
